GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » Shiller PE Ratio

Integrated Biopharma (Integrated Biopharma) Shiller PE Ratio : 2.44 (As of May. 18, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma Shiller PE Ratio?

As of today (2024-05-18), Integrated Biopharma's current share price is $0.22. Integrated Biopharma's E10 for the quarter that ended in Mar. 2024 was $0.09. Integrated Biopharma's Shiller PE Ratio for today is 2.44.

The historical rank and industry rank for Integrated Biopharma's Shiller PE Ratio or its related term are showing as below:

INBP' s Shiller PE Ratio Range Over the Past 10 Years
Min: 2.12   Med: 9.43   Max: 81
Current: 2.49

During the past years, Integrated Biopharma's highest Shiller PE Ratio was 81.00. The lowest was 2.12. And the median was 9.43.

INBP's Shiller PE Ratio is ranked better than
98.51% of 1071 companies
in the Consumer Packaged Goods industry
Industry Median: 18.88 vs INBP: 2.49

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Integrated Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.010. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.09 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Integrated Biopharma Shiller PE Ratio Historical Data

The historical data trend for Integrated Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma Shiller PE Ratio Chart

Integrated Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 57.14 22.99 5.97 3.82

Integrated Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.28 3.82 3.26 2.95 2.48

Competitive Comparison of Integrated Biopharma's Shiller PE Ratio

For the Packaged Foods subindustry, Integrated Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Biopharma's Shiller PE Ratio Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's Shiller PE Ratio falls into.



Integrated Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Integrated Biopharma's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=0.22/0.09
=2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Biopharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Integrated Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.01/131.7762*131.7762
=0.010

Current CPI (Mar. 2024) = 131.7762.

Integrated Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.000 100.560 0.000
201409 0.010 100.428 0.013
201412 0.010 99.070 0.013
201503 -0.010 99.621 -0.013
201506 -0.010 100.684 -0.013
201509 0.010 100.392 0.013
201512 -0.003 99.792 -0.004
201603 0.002 100.470 0.003
201606 0.040 101.688 0.052
201609 0.030 101.861 0.039
201612 -0.004 101.863 -0.005
201703 0.010 102.862 0.013
201706 0.070 103.349 0.089
201709 -0.010 104.136 -0.013
201712 -0.020 104.011 -0.025
201803 0.010 105.290 0.013
201806 0.028 106.317 0.035
201809 0.010 106.507 0.012
201812 0.010 105.998 0.012
201903 0.030 107.251 0.037
201906 0.010 108.070 0.012
201909 0.010 108.329 0.012
201912 0.030 108.420 0.036
202003 0.030 108.902 0.036
202006 0.060 108.767 0.073
202009 0.030 109.815 0.036
202012 0.040 109.897 0.048
202103 0.040 111.754 0.047
202106 0.140 114.631 0.161
202109 0.020 115.734 0.023
202112 0.030 117.630 0.034
202203 0.030 121.301 0.033
202206 0.050 125.017 0.053
202209 -0.001 125.227 -0.001
202212 -0.010 125.222 -0.011
202303 0.001 127.348 0.001
202306 0.001 128.729 0.001
202309 -0.002 129.860 -0.002
202312 -0.010 129.419 -0.010
202403 0.010 131.776 0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Integrated Biopharma  (OTCPK:INBP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Integrated Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrated Biopharma (Integrated Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.
Executives
Damon Desantis director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe director, 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca director 72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay director, 10 percent owner, officer: Chairman and CEO C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker director STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach director, officer: President and CEO
Glenn Chang director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov director C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva director, officer: Vice President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay director, officer: Vive President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick director C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi officer: Chief Financial Officer 14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis director, 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431